Hadasit profiles breadth of its innovative technology pipeline
This article was originally published in Clinica
There are few medtech sectors in which technology transfer company Hadasit does not have a stake. With a range of novel medical inventions under its belt, the Israeli firm believes it has a strong IP position. Clinica's Claire Thomas caught up with marketing VP Stewart Bernstein to ask about the company's plans to capitalise on its diverse product pipeline
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.